Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in ...

Shares of Stifel Financial were moving higher after it reported fourth-quarter adjusted earnings that beat Wall Street ...

Barry Bannister, Stifel chief equity strategist, joins 'Power Lunch' to discuss the bad signs for the market and the DeepSeek ...

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

Stifel Nicolaus analyst Ian Gillies maintained a Buy rating on Badger Infrastructure Solutions (BADFF – Research Report) today and set a price ...

In a report released yesterday, Brian Chin from Stifel Nicolaus maintained a Hold rating on Teradyne (TER – Research Report). The company’s ...

Stifel chief executive Ron Kruszewski said surging markets have forced firms to be particularly choosy about which advisors ...

Q4 2024 Earnings Conference Call January 29, 2025 9:30 AM ETCompany ParticipantsJoel Jeffrey - Senior Vice President ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $125.6, a high estimate of $135.00, and a low estimate of $115.00. This upward trend is evident, ...

After the market closed yesterday, Stifel published new coverage on Datadog. The firm downgraded its rating on the stock from ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.